University of Trieste

MONDAY, March 31, 2025 -- For patients with out-of-hospital cardiac arrest (OHCA), the proportion receiving layperson bystander life support (BLS) has increased, but a critical factor in determining survival and long-term outcomes is how quickly cardiopulmonary resuscitation (CPR) is initiated, according to a study presented at the annual ESC Acute CardioVascular Care congress, held from March 14 to 15 in Florence, Italy. Aneta Aleksova, M.D., from the University of Trieste in Italy, and colleagues examined whether the percentage of layperson initial rescuers has changed over time in the setting of OHCA during ST-elevation myocardial infarction (STEMI). Data were included for 172 patients with OHCA among 3,315 with STEMI admitted in Italy between 2003 and 2024. The researchers found that 26 percent of the patients with OHCA were initially rescued by a layperson. The percentage of layperson BLS increased constantly, from 26 percent in 2003-2007 to 69 percent in 2020-2024. The median time to return of spontaneous circulation (ROSC) was 10 minutes. Compared with emergency medical service (EMS) CPR, longer ROSC was seen with layperson-initiated BLS (20 versus 5 minutes). Patients who received layperson BLS more frequently underwent endotracheal intubation than those receiving EMS CPR (91 versus 65 percent). Overall, 44 patients died during their hospital stay, with no difference seen by type of initial rescuer. On logistic regression analysis and after correction for rescuer type, predictors of in-hospital mortality included worse left ventricular ejection fraction, longer time to ROSC, and older age (odds ratios, 1.38, 1.38, and 1.46, respectively). Long-term outcome did not differ according to initial rescuer. "Our data highlights the importance of immediate resuscitation and underlines the importance to promote population awareness and BLS training to further improve survival after OHCA," the authors write. Press Release More Information Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

TUESDAY, March 18, 2025 -- It doesn’t matter if CPR is performed by a doctor, a paramedic or an unskilled, unpracticed passerby -- when performed promptly, it will increase a person’s odds of survival, a new study says. The speed of CPR initiation is crucial to survival and better outcomes related to cardiac arrest, rather than who performs it, researchers reported Friday at a meeting of the European Society of Cardiology in Florence, Italy. Patients who got bystander CPR had the same risk of death during their hospital stay as those treated by a paramedic or other medical professional, researchers found. “Our data highlights the importance of immediate resuscitation and underlines the importance to promote population awareness and Basic Life Support training to further improve survival after out-of-hospital cardiac arrest,” said the research team led by Aneta Aleksova, an associate professor with the University of Trieste in Italy. For the study, researchers analyzed data from more than 3,300 people who suffered a heart attack and were admitted to the University Hospital Trieste for treatment between 2003 and 2024. The percentage of people who received bystander CPR after they first collapsed steadily increased over the years, researchers found. Only 26% of patients received bystander CPR in 2003-2007, but by 2020-2024 that had increased to 69%, results show. Each five-minute delay in the return of spontaneous heartbeat was associated with a 38% increased risk of death, researchers said. About 26% of patients died during their hospital stay, but there was no difference between who received bystander versus paramedic CPR, researchers found. During average follow-up of seven years, 14% of patients died. Long-term outcomes did not differ based on who first provided CPR, results show. “Rapid return of spontaneous circulation was crucial for in-hospital survival, independently of rescuer type,” researchers said. “Also, similar long-term survival was observed comparing patients with initial layperson or emergency medical service cardiopulmonary resuscitation.” Findings presented at medical meetings should be considered preliminary until published in a peer-reviewed journal. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

MILAN--(BUSINESS WIRE)-- Enthera Pharmaceuticals (“Enthera”), a biotech company developing first-in-class biologics for selected autoimmune conditions, today announces the appointment of Filippo Canducci MD, PhD as Chief Medical Officer. Dr. Canducci brings more than 20 years of experience in translational medicine, clinical research and drug development in inflammatory and autoimmune diseases. Prior to joining Enthera, Dr. Canducci was a senior medical leader at Roche where he led global teams in the clinical development of immunology and infectious disease assets from clinical entry through transitioning to Phase 3. At Enthera, he will be responsible for the clinical development of the company’s lead asset, Ent001, a first-in-class monoclonal antibody (mAb) designed to target the IGFBP3/TMEM219 axis, a pathway which plays a critical role in both inflammatory bowel disease (IBD) and type 1 diabetes (T1D). Dr. Canducci will also oversee the progress of Enthera’s additional pipeline candidates as the company builds out its proprietary discovery platform for the development of safe and effective, first-in-class biologics for the treatment of autoimmune diseases. “Filippo’s deep scientific and industry experience cultivated across internationally renowned biopharmaceutical companies and research institutes, along with his entrepreneurial mindset, makes him the ideal candidate to guide us as we enter the clinic with Ent001,” said Aled Paton Williams, CEO of Enthera. “We will benefit from his wealth of knowledge, particularly in the field of autoimmune diseases, as we work towards bringing novel therapeutics to underserved patient populations.” “Enthera’s portfolio of first-in-class selective inhibitors based on the novel scientific discovery of the IGFBP3/TMEM219 pathway, showcases the company’s truly innovative approach to a challenging disease area,” said Filippo Canducci, Chief Medical Officer of Enthera. “Ent001 is the only drug of its kind currently in development with the potential to halt and possibly reverse disease progression in both IBD and T1D. I look forward to working with the Enthera team to guide Ent001’s rapid entry into the clinic and to building-out the company’s pipeline.” Filippo Canducci holds an MD from Università Cattolica del Sacro Cuore in Rome, a PhD from the University of Trieste, and an MBA from SDA Bocconi - School of Management. Dr. Canducci has been published in more than 80 scientific papers in peer-reviewed high impact journals. About Enthera Pharmaceuticals Enthera Srl is a biotech company developing first-in-class biologics to transform the treatment paradigm for specific autoimmune conditions by re-establishing stem cell capabilities. The Company’s primary target indications are inflammatory bowel disease (IBD) and type 1 diabetes (T1D). Enthera’s pioneering approach capitalizes on the key discovery of the IGFBP3/TMEM219 pathway, which is involved in stem cell and beta cell apoptosis in the gut and pancreas, respectively. Enthera’s lead program, Ent001, is the only drug in development with the potential to restore the original intestinal structure in IBD and the endogenous pancreatic stem cell compartment in T1D, resulting in restoration of organ function. Enthera is a private company headquartered in Milan, Italy and founded in 2016 by Prof Paolo Fiorina and Dr Francesca D’Addio at BiovelocITA, Italy’s first biotech accelerator. The Company is backed by Sofinnova Partners, AbbVie, JDRF T1D Fund, Roche and a number of private investors. Enthera’s discovery engine and assets are protected by a broad portfolio of patents. View source version on businesswire.com: Contacts For further information: Enthera Pharmaceuticals Aled Williams, CEO info@entherapharmaceuticals.com Trophic Communications Valeria Fisher or Veronika Máté +49 175 8041816 or +49 160 90816161 enthera@trophic.eu Source: Enthera Pharmaceuticals View this news release online at: